Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 8/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18519852 | 0.81 | PNP (0.45) | PNPALDH1A1TK1XDHTSHR | |
| SCHEMBL23228201 | 0.81 | XDH (0.36) | PNPALDH1A1THRBL3MBTL1XDH | |
| SCHEMBL23679550 | 0.81 | PNP (0.45) | PNPTK1XDHUSP2TSHR | |
| SCHEMBL22381533 | 0.78 | PNP (0.42) | PNPALDH1A1TK1XDHUSP2 | |
| SCHEMBL18521164 | 0.77 | SMN1; SMN2 (0.51) | PNPALDH1A1L3MBTL1TK1XDH | |
| SCHEMBL22901876 | 0.77 | PNP (0.41) | PNPALDH1A1TK1XDH | |
| SCHEMBL18521156 | 0.77 | PNP (0.45) | PNPALDH1A1TK1USP2TSHR | |
| SCHEMBL23619480 | 0.76 | PNP (0.41) | PNPTK1XDHHBB | |
| SCHEMBL23867065 | 0.73 | PNP (0.35) | PNPTK1 | |
| SCHEMBL10671324 | 0.72 | PNP (0.42) | PNPTK1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | PNP 384/4885ALDH1A1 3999/4885THRB 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.